Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study

Tumor-size responses to first-line is a predictor of overall survival in metastatic colorectal cancer

(2019) Lola-Jade Palmieri et al.   EUROPEAN RADIOLOGY

Liver resection is justified for patients with bilateral multiple colorectal liver metastases: A propensity-score-matched analysis

(2018) Kiyohiko Omichi et al.   EJSO

Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer—central evaluation of FIRE-3

(2018) D.P. Modest et al.   EUROPEAN JOURNAL OF CANCER

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer

(2017) Alan P. Venook et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

(2017) Harpreet S Wasan et al.   LANCET ONCOLOGY

Hepatic intra-arterial injection of irinotecan drug eluting beads (DEBIRI) for patients with unresectable colorectal liver metastases: A systematic review

(2017) Olaguoke Akinwande et al.   SURGICAL ONCOLOGY-OXFORD

PARAGON II – A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer

(2016) R.P. Jones et al.   EJSO

Comparison of tumor response assessment methods in patients with metastatic colorectal cancer after locoregional therapy

(2016) Olaguoke Akinwande et al.   JOURNAL OF SURGICAL ONCOLOGY

Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis

(2015) Robert C. G. Martin et al.   CANCER

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

(2015) Chiara Cremolini et al.   LANCET ONCOLOGY

Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials

(2015) Giuseppe Aprile et al.   Oncotarget

Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial

(2014) T. Gruenberger et al.   ANNALS OF ONCOLOGY

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

(2014) Volker Heinemann et al.   LANCET ONCOLOGY

Floxuridine Hepatic Arterial Infusion Associated Biliary Toxicity Is Increased by Concurrent Administration of Systemic Bevacizumab

(2013) Andrea Cercek et al.   ANNALS OF SURGICAL ONCOLOGY

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials

(2012) Carsten Bokemeyer et al.   EUROPEAN JOURNAL OF CANCER

Irinotecan Drug-Eluting Beads in the Treatment of Chemo-Naive Unresectable Colorectal Liver Metastasis with Concomitant Systemic Fluorouracil and Oxaliplatin: Results of Pharmacokinetics and Phase I Trial

(2012) Robert C. G. Martin et al.   JOURNAL OF GASTROINTESTINAL SURGERY

The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus

(2012) R. Adam et al.   ONCOLOGIST

A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection

(2011) R. Wong et al.   ANNALS OF ONCOLOGY

Toxicity of Irinotecan-Eluting Beads in the Treatment of Hepatic Malignancies: Results of a Multi-Institutional Registry

(2010) R. C. G. Martin et al.   CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY

Conversion to Resectability Using Hepatic Artery Infusion Plus Systemic Chemotherapy for the Treatment of Unresectable Liver Metastases From Colorectal Carcinoma

(2009) Nancy E. Kemeny et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial

(2009) Gunnar Folprecht et al.   LANCET ONCOLOGY